Clinical Trials

Ovarian Neoplasms

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Phase 2/3 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07219238 2025-10-21

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

175 enrolled

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

600 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07177716 2025-09-17

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

120 enrolled

Uterine Cervical Neoplasms

NCT06321068 2025-08-14

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

5 enrolled

Endometrial Neoplasms

NCT02641639 2025-03-24

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

70 enrolled 16 charts

Platinum Resistant Ovarian Cancer

NCT06123884 2025-02-10

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Phase 2/3 Recruiting

526 enrolled

Phase 2/3 Enrolling by invitation

Uterine Cervical Neoplasms

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

510 enrolled

Uterine Cervical Neoplasms

NCT05797831 2024-05-02

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Phase 2/3 Recruiting

268 enrolled

Phase 2/3 Not yet recruiting

Endometrial Neoplasms

NCT06211023 2024-01-18

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

520 enrolled

Ovarian Neoplasms

NCT04864782 2024-01-12

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

46 enrolled

Uterine Cervical Neoplasms

NCT02490488 2020-12-08

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

248 enrolled

Ovarian Neoplasms

NCT00443196 2018-03-12

Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

150 enrolled

Adenocarcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00003880 2015-04-16

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

132 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00264732 2013-05-29

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

251 enrolled

Uterine Cervical Dysplasia

NCT00327444 2013-01-01

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

58 enrolled 11 charts

Ascites, Ovarian Neoplasms

NCT00243685 2012-01-26

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

BreastGynecologicSarcomaThoracic

150 enrolled

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00418574 2011-11-24

MIMOSA

888 enrolled 17 charts

Ovarian Neoplasms

NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group